Contributions
Abstract: EP1747
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
We report the case of a 41-year-old female with relapsing-remitting multiple sclerosis. Six weeks following her second treatment with alemtuzumab she developed recurrent genital and mouth ulceration. The results of a serum auto-immune and vasculitis screen were unremarkable and biopsy of the lesions showed epidermal ulcerations.
On the first occasion, her ulcers improved with oral steroid treatment over five days. Two further recurrences responded well to the use of topical steroids.
The occurence of these skin manifestations appeared to be related to treatment with alemtuzumab and the patient met the clinical criteria for the diagnosis of Behçet's disease. To our knowledge this is the first reported case of alemtuzumab therapy followed by Behçet's disease.
Disclosure:
Sebastian Luppe: has previously accepted speakers fees and/or hospitality from Lundbeck, Serono, and Novartis.
Beth Wright: nothing to disclose.
Janet Angus: nothing to disclose.
Emma Ormerod: nothing to disclose.
Kirsty Inglis: has previously accepted speakers fees and/or hospitality from Serono, Biogen, and Novartis.
David Cottrell: has previously accepted speakers fees and/or hospitality from Serono, Biogen, and Novartis.
Abstract: EP1747
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
We report the case of a 41-year-old female with relapsing-remitting multiple sclerosis. Six weeks following her second treatment with alemtuzumab she developed recurrent genital and mouth ulceration. The results of a serum auto-immune and vasculitis screen were unremarkable and biopsy of the lesions showed epidermal ulcerations.
On the first occasion, her ulcers improved with oral steroid treatment over five days. Two further recurrences responded well to the use of topical steroids.
The occurence of these skin manifestations appeared to be related to treatment with alemtuzumab and the patient met the clinical criteria for the diagnosis of Behçet's disease. To our knowledge this is the first reported case of alemtuzumab therapy followed by Behçet's disease.
Disclosure:
Sebastian Luppe: has previously accepted speakers fees and/or hospitality from Lundbeck, Serono, and Novartis.
Beth Wright: nothing to disclose.
Janet Angus: nothing to disclose.
Emma Ormerod: nothing to disclose.
Kirsty Inglis: has previously accepted speakers fees and/or hospitality from Serono, Biogen, and Novartis.
David Cottrell: has previously accepted speakers fees and/or hospitality from Serono, Biogen, and Novartis.